The IASLC Lung Cancer Staging Project: Proposals for the Inclusion of Broncho-Pulmonary Carcinoid Tumors in the Forthcoming (Seventh) Edition of the TNM Classification for Lung Cancer

Abstract

In summary, the IASLC proposals for the 7th edition of TNM are helpful in predicting prognosis for broncho-pulmonary carcinoid tumors. It is the recommendation of the IASLC Staging project that TNM be applied to broncho-pulmonary carcinoid tumors. A prospective collection of data through an International Registry of Pulmonary Neuroendocrine Tumors planned by the IASLC will allow for further detailed analysis of staging data for broncho-pulmonary carcinoids.

Analysis on the Characteristics and Prognosis of Pulmonary Neuroendocrine Tumors

“…In this study, in order to compare the clinical, pathological and prognostic differences between different types of pulmonary NET, we used the 7th edition of American Joint Committee On Cancer/Union For International Cancer Control (AJCC/UICC) TNM staging system (Edge et al, 2010). The reason for applying the TNM staging system was chiefly on the basis of two large-scale surveys on carcinoid tumors and SCLC from International Associational Association for the Study of Lung Cancer (IASLC) database (Travis et al, 2008;Vallieres et al, 2009). OS was the main endpoint of this study.…”

Limited role of Ki-67 proliferative index in predicting overall short-term survival in patients with typical and atypical pulmonary carcinoid tumors

“…Atypical carcinoids have 2-10 mitotic figures per mm 2 (or per 10 high power fields) and focal tumor necrosis. [3][4][5] Patient cohorts with atypical carcinoids have a worse prognosis than those with typical carcinoids, but the clinical behavior of individual tumors remains unpredictable, with both tumors having the potential to metastasize and/or recur. 6,7 As histological diagnosis provides somewhat limited prognostic information for individual patients with pulmonary carcinoid tumors, 8 a variety of candidate prognosticators have been investigated, including tumor location within the lung, mutations, deletions, and/or instability in chromosomes, oncogenes, and/ or tumor suppressor genes, cell/nuclear morphometry, Rb inactivation, p16, cyclin B1, cyclin D1, BCl2, Bax expression, microsatellite instability, DNA ploidy, S-phase fraction, extent of apoptosis, and Ki-67 immunoreactivity.…”

Akciğer Kanserinde Evreleme: Yenilikler

“…KHAK ve küçük hücreli olmayan tümörlerde olduğu gibi karsinoid tümörlerde de TNM evresi arttıkça 5 yıllık sağkalımda belirgin azalma dikkati çekmiştir [16]. Karsinoid tümörlerde tahmin edilen 5 yıllık sağkalım oranları evre I, II, III, ve IV için sırası ile %93, % 85, %75 ve %57 olarak belirlenmiştir [5]. Tanımlanan bulgular temelinde bu kanser tipinde 7. sürüm evrelemenin kullanılabileceği vurgulanmıştır.…”

“…Uluslararası akciğer kanser evreleme komitesi bu amaçla, 2005 yılında yayınlanan TNM evrelemesi 6. sürü-münü 2009 yılında güncelleyerek 2010 yılının temmuz ayında 7. sürüm olarak yayınladı [2]. Küçük hücreli dışı akciğer kanseri evrelemesinde önemli değişiklikleri içeren 7. sürüm TNM evreleme kılavuzu ile küçük hücreli kanserlerin ve bronkopulmoner karsinoid tümörlerin evrelemesi de mümkün hale geldi [3][4][5]. Yeni kıla-vuzda tedavi ve prognoz farklılıkları göz önüne alınarak T ve M evrelemesinde yenilikler yapıldı (Tablo 1).…”